Kura Oncology, Inc. (KURA)
NASDAQ: KURA · Real-Time Price · USD
9.01
-0.30 (-3.22%)
At close: Jul 31, 2026, 4:00 PM EDT
9.17
+0.16 (1.78%)
After-hours: Jul 31, 2026, 7:34 PM EDT
Kura Oncology Stock Forecast
Stock Price Forecast
According to 15 analysts polled by S&P Global, Kura Oncology stock has a consensus rating of "Strong Buy" and an average price target of $31.17. The average 1-year stock price forecast is 245.95% higher than the current stock price, while the lowest is $15 (+66.48%) and the highest is $76 (+743.51%).
Price Target: $31.17 (+245.95%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Kura Oncology stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 11 | 11 | 12 | 12 | 12 | 12 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 14 | 15 | 15 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Bank of America Securities | Bank of America Securities | Buy Maintains $30 | Buy | Maintains | $30 | +232.96% | Jul 28, 2026 |
| Barclays | Barclays | Buy Maintains $28 | Buy | Maintains | $28 | +210.77% | Jul 28, 2026 |
Unknown Analyst Wedbush No rating | Wedbush | Buy Maintains $36 | Buy | Maintains | $36 | +299.56% | Jul 28, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Maintains $28 | Buy | Maintains | $28 | +210.77% | Jul 27, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $40 | Buy | Reiterates | $40 | +343.95% | Jul 27, 2026 |
Financial Forecast
Revenue This Year
95.04M
from 67.48M
Increased by 40.84%
Revenue Next Year
214.56M
from 95.04M
Increased by 125.75%
EPS This Year
-3.44
from -3.18
EPS Next Year
-2.58
from -3.44
EPS and Forward PE are based on non-GAAP adjusted numbers.